ライフサイエンスコーパス: cross-protection

1 V-ADVISE model ($191 800 when assuming 4vHPV cross-protection).

2 illustrating the potential of Th17-mediated cross protection.

3 There is also evidence of cross protection.

4 inant PC epitope on SPn capable of providing cross protection.

5 y for poliovirus type 2, suggesting possible cross protection.

6 ediated cross-reactivity and associated with cross protection.

7 allenge, respectively, indicating incomplete cross-protection.

8 Both T lymphocytes and Ab contribute to such cross-protection.

9 have been described, but they do not lead to cross-protection.

10 aled little role for serum or mucosal Abs in cross-protection.

11 development of a pandemic vaccine with broad cross-protection.

12 splayed differences in cross-recognition and cross-protection.

13 tion, assuming for HPV45 either 95% or lower cross-protection.

14 helical region of PspA in the elicitation of cross-protection.

15 o react with HIV-1 that could play a role in cross-protection.

16 in frequent infections and a lack of durable cross-protection.

17 binding by a SIT-induced IgG and thus limit cross-protection.

18 may play a critical role in vaccine-induced cross-protection.

19 rated by 6 months additionally provided some cross-protection.

20 ed RMs were challenged with SVV to determine cross-protection.

21 (RR 0.72, 95% CI 0.54-0.96), which suggests cross-protection.

22 ed infection and a group with some degree of cross-protection.

23 t with epidemiologic estimates of VE showing cross-protection.

24 Gnotobiotic piglets were used to investigate cross-protection.

25 heless capable of contributing to long-lived cross-protection.

26 f 1.06-2.06 for the first wave and, assuming cross-protection, 1.21-3.58 in the second.

27 ucted to gain insight into the high level of cross-protection afforded by RotaTeqTM against these G8

28 This superior cross-protection afforded by the CLDC adjuvant required

29 out showing weight loss and confers complete cross protection against lethal challenge with heterolog

30 d-type (WT) GP/VSVDeltaG and did not provide cross protection against Sudan virus.

31 implies that lactoferrin could provide broad cross protection against the enteropathogens that share

32 disease remains essential, as the extent of cross protection against vaccine-related serotypes is st

33 ty of Shigella group B, a strategy for broad cross-protection against 14 Shigella flexneri serotypes

34 o of the three truncated PspAs each elicited cross-protection against 71%-100% of the S. pneumoniae c

35 firm its infectivity for calves and complete cross-protection against a bovine coronavirus (DB2 strai

36 ns, because rejection of mKSA did not induce cross-protection against a challenge with parental 4T1.

37 ermine if this vaccine regimen could provide cross-protection against a genetically diverse species,

38 ther seasonal influenza vaccination provides cross-protection against A(H3N2)v virus.

39 plant developmental responses and resultant cross-protection against biotic stress.

40 tion with TC-PC177 failed to induce complete cross-protection against challenge by the highly virulen

41 Vaccination with PIV5-N1 NA provided cross-protection against challenge with a heterosubtypic

42 e whether infection with TC-PC177 can induce cross-protection against challenge with a highly virulen

43 important, the HA-DNA vaccine conferred 95% cross-protection against challenge with lethal antigenic

44 al/HK/W312/97 ca virus provided the broadest cross-protection against challenge with three antigenica

45 he 1-to-115 fragment, however, elicited some cross-protection against clades 2 and 4 in BALB/c mice b

46 nteraction pattern, suggesting immunological cross-protection against coxsackievirus B1.

47 In this study, we explored the mechanism of cross-protection against cutaneous lesion-causing Leishm

48 ighly efficient in induction of long-lasting cross-protection against different influenza virus strai

49 domonas yielded significant but not absolute cross-protection against different strains of P. aerugin

50 formulation to specific immune cells, enable cross-protection against divergent strains, act as adjuv

51 animals vaccinated with the cVLP showed 20% cross-protection against drifted (Philippines) and 60% p

52 Current flu vaccines have failed to provide cross-protection against evolving viruses in the field.

53 y responses, involved in providing long-term cross-protection against H3N2 influenza virus when compa

54 against 2 unrelated pathogens and stimulate cross-protection against H5N1 influenza viruses.

55 mucosal M2e antibody responses and conferred cross-protection against heterosubtypic H1N1, H3N2, and

56 fferences in protective immunity, especially cross-protection against heterovariant and heterosubtypi

57 d a role for latent herpesvirus infection in cross-protection against infection and exacerbation of c

58 influenza A virus infection may not provide cross-protection against influenza B virus infection.

59 Heterosubtypic immunity (HSI) is defined as cross-protection against influenza virus of a different

60 ion of mice with Ldp27(-/-)also demonstrated cross-protection against Leishmania major and Leishmania

61 cines ID83/GLA-SE and ID93/GLA-SE may confer cross-protection against M. leprae infection.

62 protection against M. tuberculosis, induces cross-protection against M. leprae that is comparable or

63 nce both supporting and opposing the idea of cross-protection against microbial pathogens and insect

64 ategy of mucosal vaccination that stimulates cross-protection against multiple influenza virus subtyp

65 nstrating that Th17 memory cells can provide cross-protection against multiple serotypes of Klebsiell

66 ults indicated that rAPMV3 alone can provide cross-protection against NDV challenge.

67 uced by inactivated vaccines provide limited cross-protection against new viral serotypes.

68 pes in cancer) and vaccine properties (i.e., cross-protection against non-targeted HPV types), compar

69 se include duration of protection, degree of cross-protection against nonvaccine types, efficacy in m

70 Partial cross-protection against other HPV types has been report

71 of one strain of E. chaffeensis would confer cross-protection against other strains needs to be inves

72 HPV16/18 vaccines offer cross-protection against other types, for example, HPV45

73 eric VK210/247 antigen can elicit high level cross-protection against parasites expressing either CSP

74 g amino acids 314 to 418 were able to elicit cross-protection against pneumococci expressing PspA pro

75 A (rPspA)/EF5668, like rPspA/Rx1, can elicit cross-protection against pneumococci of different capsul

76 that cellular immunity is crucial to mediate cross-protection against reinfection with a different se

77 role of cross-reactive immunity in mediating cross-protection against secondary heterotypic DENV infe

78 Subsequent studies showed that PCV7 provided cross-protection against serotype 6A but not serotype 6C

79 lular immune response that conferred partial cross-protection against simian varicella virus (SVV) ch

80 epitope of vaccinia virus that will provide cross-protection against smallpox in HLA-A2.1-positive i

81 PCV10 might provide cross-protection against some vaccine-related serotypes.

82 This effect was tumor-specific, since no cross-protection against syngeneic, ganglioside GD2+ EL-

83 immunization with contemporary TIV provides cross-protection against the 1918 virus in ferrets.

84 The extent of cross-protection against the heterologous parasite strai

85 e inactivated vaccines do not provide robust cross-protection against the multiple antigenic variants

86 0 to 2000, to induce cross-reactivity to and cross-protection against the pandemic swine-origin H1N1

87 ns that circulated 50-60 y ago might provide cross-protection against the swine-origin 2009 H1N1 infl

88 d induce cross-reactive T-cell responses and cross-protection against the tumor.

89 r, suggesting that LAIV provided substantial cross-protection against this variant influenza A virus

90 nst the homologous virus and provided strong cross-protection against two heterologous species of cas

91 Some B cell subsets provide extensive cross-protection against variants of the ever-mutating v

92 To assess the potential for cross-protection among genital human papillomavirus (HPV

93 Cross-protection among pneumococcal serotypes within ser

94 neered mild (essentially symptomless)-strain cross protection and RNA-mediated transgenic resistance.

95 V vaccines for T cell responses might confer cross-protection and prevent antibody-mediated enhanceme

96 emic is plausible given sufficient levels of cross-protection are attained via natural infection duri

97 Therefore, high levels of cross-protection are predicted in the mouse model.

98 Influenza vaccines with broad cross-protection are urgently needed to prevent an emerg

99 In vivo cross-protection assays showed that a substantial portio

100 Thus, some conjugate vaccines may elicit cross-protection better than others.

101 JEV-endemic areas, and clinical data suggest cross-protection between DENV and JEV.

102 ngly suggest that while there may be limited cross-protection between highly (>85% L1 amino acid iden

103 dge of immune mechanisms responsible for the cross-protection between highly divergent viruses such a

104 overlapping subsets of antigenic variants if cross-protection between pathogen types sharing any vari

105 risingly, however, we found no difference in cross-protection between respiratory-deficient and wild-

106 nfections, there is reciprocal immunological cross-protection between spotted fever group and typhus

107 In this article, we examine the strength of cross-protection between successive waves of the 1918-19

108 Our data demonstrate that cross-protection between the EBOV species can be achieve

109 Additionally, studies of cross-protection between the newly identified emerging G

110 V (PRV) G9P[13] and evaluated the short-term cross-protection between this strain and human RV (HRV)

111 ironmental stress response (ESR) and for the cross-protection by a preliminary heat stress (or slow g

112 ant level does not appear to explain partial cross-protection by the bivalent HPV vaccine.

113 ica Vaccine Trial (CVT) demonstrated partial cross-protection by the bivalent human papillomavirus (H

114 In mice, cross-protection can also be elicited by systemic immuni

115 Cross-protection can be achieved by activating CD8+ and

116 In this paper, we show that cross-protection can be conferred by adoptively transfer

117 accelerated clearance of a new viral strain (cross-protection) can be elicited by prior infection (he

118 ood model fit for the two-serotype TSIR with cross-protection, capturing the seasonality and geograph

119 g, and the EV71 vaccine does not give useful cross-protection, despite the capsid proteins of the two

120 This response provides cross-protection during subsequent proteotoxic stress, s

121 Cross-protection elicited by these three fragments was e

122 lso high, with little non-cognate biological cross-protection evident under physiological conditions.

123 tion against reinfection with all serotypes (cross-protection), followed by lifelong immunity to the

124 period of resistance against all serotypes (cross-protection), followed by lifelong resistance to th

125 ies of human subjects to suggest a window of cross-protection following DENV infection since Sabin's

126 The duration and strength of cross-protection following infection with EV-A71 or CV-A

127 We previously demonstrated a role in cross-protection for pre-existing cross-reactive Abs, ma

128 oint of view of gene expression patterns and cross-protection for survival.

129 iant influenza viruses generated significant cross-protection for the recipients and indirect (herd)

130 CLDC-adjuvanted vaccine provided significant cross-protection from either a sublethal or lethal influ

131 A degree of vaccine-induced cross-protection has also been demonstrated against gene

132 Limited or no cross-protection has been demonstrated between the T. pa

133 This, plus observations on short-term cross-protection, have implications for vaccination and

134 tential vaccine targets capable of eliciting cross-protection immunity against pneumococcal infection

135 The cross-reactive antibodies afforded cross-protection in a mouse model system.

136 emic and mucosal sites, boosting significant cross-protection in animals against heterologous viruses

137 her HI nor VN testing provides correlates of cross-protection in ferrets.

138 s are needed to fully evaluate the extent of cross-protection in humans among the variants and protot

139 Wa G1P[8] and generated complete short-term cross-protection in pigs challenged with HRV or PRV, whe

140 f FimA as a common immunogen able to provide cross-protection in streptococcal endocarditis by determ

141 We suggest that cross-protection in the common mucosal immune system is

142 human or AGM sera between RSV and PVM and no cross-protection in the mouse model.

143 indicate that these O antigens do not confer cross-protection in vivo.

144 pertussis has been attributed to the lack of cross protection induced by pertussis vaccines.

145 igens, suggesting they are not necessary for cross-protection induced by carriage.

146 No lasting cross protection is afforded to heterologous serotypes f

147 The cross-protection is associated with a high level of vacc

148 rily mediated by virus-neutralizing Abs, the cross-protection is associated with Abs directed to cons

149 The clinical benefit of cross-protection is not expected to be fully additive to

150 The basis for the observed variation in cross-protection is not known, but our results suggest t

151 ability of these common epitopes to provide cross-protection is unknown.

152 e data also suggest that complex patterns of cross-protection may exist across NoV genotypes in human

153 ge cells were found to be important for this cross protection mediated by immune sera.

154 we investigated peptide vaccination induced cross-protection mediated by CD8(+) T cells in two autoi

155 The two strains form a successful cross-protection mutualism without a period of coevoluti

156 cherichia coli strains can form an effective cross-protection mutualism, protecting each other in the

157 onse to A(H3N2)v is consistent with the poor cross-protection observed among TIV-immune animals.

158 c understanding of the nature of serological cross-protection observed in people over 60 years of age

159 Cross-protection occurs because potentially pathogenic s

160 specificity, cross-reactivity, affinity and cross-protection of mAb102.1F10 towards homologous calci

161 This result can explain the previously noted cross-protection of osmotic stress against oxidative and

162 than 20 years of age, with no indication of cross-protection or herd effects.

163 tanding of the mediators responsible for the cross-protection period is important for vaccine design,

164 The duration and mechanisms of the transient cross-protection period remain elusive.

165 munization approach, we observed an improved cross-protection rate, with 5 of 6 guinea pigs surviving

166 However, the mechanisms responsible for such cross-protection remain elusive.

167 tion and determine the level of coverage and cross-protection required to reduce or eliminate the inf

168 These cross-protection results complement the vaccine's prophy

169 specific virus and host responses, including cross-protection, systemic virus movement, hypersensitiv

170 When assuming no 4vHPV cross-protection, the incremental cost per quality-adjus

171 itivity analyses in the scenario of no 4vHPV cross-protection, the simplified model results ranged fr

172 e reemergence of SARS-CoV but also providing cross-protection, thus interrupting zoonotic transmissio

173 with M2 VLP supplemented vaccine transferred cross protection to naive mice.

174 by PSRV in Hawaii, starting from the use of cross protection to parasite-derived resistance with tra

175 tween different influenza strains may impart cross-protection to H5N1 strain of influenza.

176 Heterosubtypic immunity (HSI) is defined as cross-protection to infection with an influenza A virus

177 The mechanisms of broad cross-protection to influenza viruses of different subty

178 inactivated pneumococcal vaccines may confer cross-protection to multiple pneumococcal serotypes and

179 influenza virus to evaluate the duration of cross-protection to the H1N1 pandemic strain by vaccinat

180 tes the contribution of cellular immunity to cross-protection using mouse models of DENV infection.

181 Additionally, cross protection was not consistently achieved in bats p

182 Cross-protection was associated with substantial expansi

183 he ability of genetic immunization to elicit cross-protection was demonstrated by the survival of imm

184 Cross-protection was found between 6B and 6A but not bet

185 ous regions of other PspAs could also elicit cross-protection was investigated.

186 Cross-protection was likely not dependent on serum virus

187 No cross-protection was seen with distantly related type B

188 nties, but not in PCV13 counties, suggesting cross-protection with 6A, which is included in PCV13.

189 nted in both countries when assuming vaccine cross-protection with both the current and second-genera

190 No cross-protection with other paramyxoviruses, such as res

191 The extent of cross-protection within a subfamily has been difficult t

192 With >/=80% coverage, even 50% cross-protection would reduce HPV45 by >/=94%.